Interní Med. 2009; 11(9): 369-375

Treatment of hypertension with a fixed combination. New evidence.

prof. MUDr. Miroslav Souček, CSc
II. interní klinika FN u sv. Anny LF MU, Brno

The guidelines for treatment of hypertension list combinations of various antihypertensives. The effect of these drugs is commonly

potentiated. However, one needs to realize the risk of lower patient adherence while having to take multiple tablets. A number of fixed

combinations are available that are easier to use and, thus, patient adherence to treatment is more likely. Adherence certainly is a problem

in hypertensives since the condition is chronic, often symptomless, and reaching the target pressure mostly requires combination

therapy. In 2008, new studies concerning the combination therapy for hypertension were published that have a major impact on everyday

practice and may positively affect the treatment of our patients.

Keywords: hypertension, combination therapy, fixed combination.

Published: October 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M, CSc. Treatment of hypertension with a fixed combination. New evidence. Interní Med. 2009;11(9):369-375.
Download citation

References

  1. Widimský J jr, Cífková R, Špinar J, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Vnitř Lék 2008; 54 (1): 101-118. Go to PubMed...
  2. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
  3. Widimský J et al. Hypertenze. Praha, Triton 2008; 705 s.
  4. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixedcombination perindopril/amlodipine. Curr Med Res Opin 2008; 24: 3543-1557. Go to original source... Go to PubMed...
  5. Hannson L, Zanchetti A, Carruthers SG, et al. Effect of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized Trial. Lancet 1998; 351: 1755-1762. Go to original source... Go to PubMed...
  6. UK Prospektive Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703-713. Go to original source... Go to PubMed...
  7. Patel A and ADVANCE Collaborating Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840. Go to original source... Go to PubMed...
  8. Dluhy RG, McMahon GT. Intensive Glycemic Control in the ACCORD and ADVANCE Trials. N Engl J Med 2008; 358: 2630-2633. Go to original source... Go to PubMed...
  9. Staessen JA, Fagard R, Thijs L, et al. For the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet 1997; 360: 757-764. Go to original source... Go to PubMed...
  10. Beckett NS, Peters R, Fletcher AE, et al. For the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. Go to original source... Go to PubMed...
  11. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913. Go to original source... Go to PubMed...
  12. Jamerson KA, on behalf of the ACCOPLISH investigators. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. American College of Cardiology Scientific Sessions; March 31, 2008; Chicago, IL.
  13. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. Go to original source... Go to PubMed...
  14. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.